Shanghai Pharmaceuticals Achieves Strong Start in Q1 2026 with Diversified Business Highlights

On March 24, Cherry Huang, President of Johnson & Johnson Innovative Pharmaceuticals China, and Chen Jian, Vice President of Johnson & Johnson Innovative Pharmaceuticals China, visited the "Eli Lilly·Comprehensive Flagship Entity" under Shanghai Pharmaceutical Co., Ltd. for a tour and research. Both parties conducted in-depth discussions on core issues such as full lifecycle services for innovative drugs, collaboration with specialty pharmacies, and innovative payment solutions. They clarified the direction and implementation pathways for key project collaborations, working together to establish an end-to-end connection for innovative drugs from the research and development stage to patients.

This exchange activity further deepened the consensus of cooperation between the two parties in the field of innovative drug services, and clarified the promotion path and coordination mechanism for key projects. All parties will take this exchange as an opportunity to fully leverage their synergistic advantages in specialized pharmacies, supply chains, innovative payment solutions, and patient services, providing higher quality health security to patients through more professional, convenient, and compassionate health services.

On March 24, Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. and GlaxoSmithKline (GSK) held a grand strategic cooperation launch ceremony for the hepatitis B vaccine Engerix® in Shanghai. The two parties announced a strategic cooperation agreement regarding the import of GSK's hepatitis B vaccine Engerix® into the Chinese market, nationwide distribution operations in China, and in-depth coverage of district and county Centers for Disease Control and Prevention (CDC) and vaccination points (POV) in areas not covered by the non-GSK team. This move marks a new step forward in promoting the accessibility of vaccines and disease prevention efforts in China, providing a stronger health barrier for the general public.

With the improvement of residents' living standards and the shift in health concepts, overweight, obesity, and related chronic diseases have become significant public health issues affecting the health of the Chinese population. Scientific weight management not only requires professional drug support but also relies on convenient and accessible long-term services and health guidance. In line with this trend, on March 27, 2026, the strategic cooperation launch meeting between Shanghai Huashi Pharmacy Co., Ltd. (under SPH) and Innovent Bio was successfully held in Shanghai. The two parties will jointly create an integrated "drug + service" weight management model to contribute professional strength toward improving the overall health level in China.

Recently, the 2026 China Pharmacy Top 100 Conference was successfully held in Suzhou. As the "first conference of the year" in the pharmaceutical retail industry, this grand event brought together major pharmacy chains across China, industry experts, and leading pharmaceutical companies. SPH Guofeng participated deeply, exploring new industry opportunities with pharmaceutical retail elites nationwide, cultivating the anemia-focused blue ocean market, fully demonstrating its outstanding brand strength, and highlighting corporate responsibility. At the conference, SPH Guofeng officially launched the "Red Across China · Hongyuanda Cup" Retail Academic · Anemia Specialist Selection Activity.

From March 26th to 28th, the 11th Health Products Trading Conference and the 2026 Xiding Conference grandly opened in Huzhou. As the president unit of the Huzhou Traditional Chinese Medicine Industry Association, SPH Qingchunbao, under the leadership of the Zhejiang Province Traditional Chinese Medicine Industry Association, made a significant appearance at the exhibition. With advanced manufacturing capabilities in digitalization, intelligence, and green technology, it showcased the hard-core style of a leading national pharmaceutical enterprise at this industry event, becoming the focus of attention throughout the venue.

Recently, the certification audit team of SGS conducted a recertification audit of the energy management system for Shanghai Hutchison Pharmaceuticals. Through multi-dimensional methods such as system document review, energy assessment, on-site inspection, and personnel interviews, the audit team comprehensively evaluated the effectiveness of the company's energy management system operations. It was confirmed that the company’s energy management system complies with the requirements of GB/T 23331-2020/ISO 50001:2018 standards. The company was officially awarded the "Energy Management System Certification Certificate" recently. This recertification marks the second consecutive recertification since the company first passed the energy management system certification in March 2020. It indicates that the company’s energy management work continues to maintain a high level, standardization, and stable operation. The construction and implementation capabilities of the energy management system have once again been recognized by authoritative institutions.

Recently, the Fujian Provincial Department of Industry and Information Technology, the Provincial Health Commission, and the Provincial Drug Administration jointly released the "List of Fujian Province's Second Batch of New and Excellent Medical Devices and Classic Traditional Chinese Medicine Products." Three exclusive products from SPH Xiamen: Babao Dan, Bushen Yijing Pills, and Wenjing Baidai Pills, have successfully been included in the list due to their solid product quality and profound clinical value. This marks another official authoritative recognition for the company in inheriting classic formulations and promoting the modernization of traditional Chinese medicine.

Recently, Liaoning SPH Haohushi Pharmaceutical (Group) Co., Ltd.'s wholly-owned subsidiary — Liaoning SPH Technology Development Co., Ltd. — announced good news: the laboratory successfully passed the rigorous evaluation by the China National Accreditation Service for Conformity Assessment (CNAS) and officially obtained CNAS accreditation. This signifies that the company has reached a new level of internationally recognized standardization in quality control and testing technology.

Recently, the event "Passing the Torch of Traditional Chinese Medicine at Anshun Road, Leishih Herbal Fragrance" and the establishment of the "Anshun Road Primary School·Leishih Herb Garden" joint practice base was held at Anshun Road Primary School in Changning District, Shanghai. From the signing of the party-building cooperation agreement to the taking root of the herb garden, every step of collaboration between Anshun Road Primary School and Shanghai Lei Yun Shang Pharmaceutical Factory has been guided by the shared mission of inheriting traditional Chinese medicine culture and nurturing a new generation for the times. The completion of this herb garden is a generous gift to the youth from both the school and the enterprise, as well as a vivid example of how traditional Chinese medicine culture can take root in schools and enrich the growth of young people, allowing the wisdom of traditional Chinese medicine to shine anew in modern campuses.